Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

GlobeNewswire

May 06, 2024



Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1­

Related

---